; miR21 knockdown in rats subjected to myocardial infarction (MI) decreases AF duration and atrial fibrosis.
C ardiac structural remodeling, particularly atrial fibrosis, plays a major role in atrial fibrillation (AF). 1 Congestive heart failure (CHF) promotes atrial structural remodeling. 1 The fibrotic response is complex and incompletely understood.
2 MicroRNAs (miRs) are evolutionarily conserved short, noncoding RNAs that block mRNA translation and/or promote mRNA breakdown of target genes. 3 Recently, miR21, miR29b, and miR133a were shown to be potentially involved in cardiac fibrotic responses. [4] [5] [6] [7] [8] MiR21 enhances extracellular signal-related kinase/mitogen-activated protein kinase activity and promotes fibroblast survival disease, and heart failure and miRs may represent useful biomarkers, [10] [11] [12] we measured plasma miR21, miR29b, miR133a, and miR15 concentrations in patients with AF and/or CHF. We then quantified miR29b and miR133a expression in atrial tissue from AF patients. Finally, we used adenoassociated viruses to infect mice with miR29b knockdown or "sponge" viruses to determine the manner in which reduced miR29b expression affects tissue collagen gene expression. Our results support a potential role for miR29b in AF.
Methods
A detailed description of Methods is available in the online-only Data Supplement.
Patient Characteristics
Plasma samples were obtained from 33 patients (Table 1) with persistent AF according to American Heart Association/American College of Cardiology guidelines. 13 AF symptom score was assessed by European Society of Cardiology guidelines.
14 Patients had to be clinically compensated with resting heart rate 50 to 100 bpm during AF at the time of blood sampling. Thirty-two patients with CHF and no history of AF (as ascertained by ECG on at least 3 clinic visits) constituted the CHF-only population. The diagnosis of CHF was based on the American College of Cardiology/American Heart Association 2005 guidelines, 15 with typical symptoms and reduced echocardiographic left ventricular ejection fraction. New York Heart Association class IV patients were excluded. The AF group was subdivided into patients with (n=16) and without (n=17) CHF on the basis of the same clinical criteria. Controls were patients from surgical outpatient clinics (n=30) in whom heart disease (ECG and clinical examination), chronic inflammatory diseases, history of cancer, liver disease, or neurodegenerative disease were excluded. We measured miRs in plasma according to Mitchell et al. 16 Written informed consent under institutional review board-approved protocols (Klinikum Grosshadern, University of Munich) was obtained in all cases.
Right atrial appendages were dissected from a separate population (Table 2 ) including 19 patients with sinus rhythm, 9 with paroxysmal AF, and 8 with chronic AF (duration >6 months). Experimental protocols were approved by the ethics committee of the Medical Faculty Mannheim, Heidelberg University (No. 2011-216 N-MA). Each patient gave written informed consent. After excision, right atrial appendages were snap-frozen in liquid nitrogen.
Canine Model
Animal handling procedures followed National Institutes of Health guidelines (http://oacu.od.nih.gov/training/index.htm) and were approved by the Animals Research Ethics Committee of the Montreal Heart Institute. Ninety-four mongrel dogs (weight, 22-36 kg) were divided into 5 groups: control (n=32), sham (n=5), 24-hour ventricular tachypacing (VTP) (n=19), 1-week VTP (n=16), and 2-week VTP (n=22). Sham and VTP dogs were chronically instrumented as ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; CHF, congestive heart failure; EHRA, European Heart Rhythm Association; LV, left ventricular; NA, not available; NAP, not applicable; and NYHA, New York Heart Association.
*Receiving antihypertensive treatment. †Hypoglycemic medication. ‡Lipid-lowering drug. §Loop or thiazide diuretic. ||Not applicable because CHF absent.
¶p<0.05, #p<0.001 vs controls without CHF or AF. Each AF group was compared statistically with the corresponding group without AF.
by guest on April 30, 2017 http://circ.ahajournals.org/ Downloaded from described previously. 17 Two unipolar leads were inserted into the right ventricular apex and connected to a pacemaker implanted in the neck. Twenty-four hours postoperatively, ventricular pacing was initiated at 240 bpm (sham dogs were followed for 1 week with deactivated pacemakers). After pacing, dogs were anesthetized with morphine (2 mg/ kg SC) and α-chloralose (120 mg/kg IV, followed by 29.25 mg/kg per hour) and ventilated mechanically. The mean duration of 10-Hz burst pacing-induced AF was measured 17 as an index of AF sustainability. Left atrial (LA) tissue was removed and rapidly frozen in liquid N 2 . Tissue blocks were stored at −80°C for biochemical assays and/ or were buffered in formalin for histological analysis. Fibrosis was evaluated with Masson trichrome staining and quantified by a blinded observer (percent cross-sectional area excluding blood vessels and perivascular tissue), as described previously. 18 Atrial cells were isolated as described previously, 19 and fibroblasts were separated from cardiomyocytes. Additional atrial samples were obtained from 8, 6, 6, and 5 dogs prepared for other projects in control, 24-hour, 1-week, and 2-week VTP groups, respectively, to obtain finer resolution of the time course of biochemical changes with VTP.
Mouse Model
Animal handling procedures followed National Institutes of Health guidelines (http://oacu.od.nih.gov/training/index.htm) and were approved by the Animals Research Ethics Committee of the Montreal Heart Institute. Eighteen mice (C57BL/6) weighing 15 to 20 g (from Charles River, Wilmington, MA) were allocated into either the green fluorescent protein (GFP) control adenoassociated virus group or the miR29b sponge virus group. Mice were anesthetized with isoflurane (2%). An adenoassociated virus, serotype 9, developed for cardiotropic homing following peripheral injection, was used to transfer the miR29b sponge or a GFP control to mouse hearts via jugular vein injection to assess the in vivo consequences of miR29b downregulation. Two-hundred microliters of adenoassociated virus (2×10 11 
RNA Extraction and qPCR
Canine RNA was extracted with Trizol, and human and mouse RNA was extracted with mirVana. RNA concentration was determined by nanodrop. cDNA was synthesized with 0.5 µg (mRNA quantification) or 10 ng of total RNA (microRNA quantification). qPCR was performed with TaqMan probes and primers or custom-made SYBRGreen probes (Table I in the online-only Data Supplement).
Collagen Protein Quantification
Fibroblasts were infected with lentiviruses (miR29b sponge or miR29b overexpressing) and grown for 5 days without changing of the medium. Medium was then removed for collagen assay by Western blot. Results were normalized to fibroblast number. Proteins were separated by electrophoresis on a 6% SDS-PAGE gel and transferred to nitrocellulose membranes. Membranes were blocked overnight with 3% bovine serum albumin and incubated with anti-collagen-I primary antibody, followed by secondary antibody conjugated to horseradish peroxidase. Signals were detected with chemiluminescence.
Manipulation of Fibroblast miR29b Expression
For in vitro manipulation of miR29b expression, near-confluent (5-7 days) fibroblasts were trypsinized, counted, and plated in 12-well dishes at 100 000 cells per well. After 4 to 6 hours for recovery, cells were infected with lentiviral constructs at 50 multiplicity of infection. Cells were kept in culture for 3 to 5 days after infection, and then samples were collected for qPCR by adding 500 µL per well of Trizol, followed by snap-freezing and storage at −80°C. We manipulated miR29b expression in fibroblasts with lentiviraltransferred gene constructs. To assess changes in canine atrial fibroblast target gene expression resulting from miR29b knockdown in vitro, we used viral gene transfer ( Figure 4A ) to deliver a sponge construct (miR29b sponge) along with GFP in a bicistronic vector. The sponge was designed to physically bind miR29b by complimentary base pairing, thereby causing its cellular degradation. Lentivirus overexpressing GFP only served as a negative control. We produced miR29b overexpression with a lentivirus overexpressing the primary miR29b sequence. A virus with a scrambled shRNA embedded in a primary miR29b context was used as a negative control. For in vivo manipulation, adenoassociated virus was used to deliver the knockdown sponge or GFP control (for details of adenoassociated virus construction, see Methods in the online-only Data Supplement).
Statistical Analysis
Data are presented as mean±SEM. For the time course analysis, plasma levels of patients, and atrial tissue of patients, 1-way ANOVA was used with a post hoc Dunnett test. An unpaired t test was used for 2-group comparisons. Multivariable adjusted linear regression models were fitted to assess the associations between miR plasma concentrations in patients with AF and/or CHF while accounting for other predictors. Models were used that adjusted for (1) age and sex only; (2) coronary artery disease, hypertension, diabetes mellitus, and hypercholesterolemia in addition to age and sex; and (3) angiotensinconverting enzyme inhibitor or angiotensin II receptor type 1 blocker 
Results

MiR29b Changes in a Canine CHF-Related AF Model
We first investigated potential miR29b changes in an animal model of AF-promoting, CHF-related structural remodeling. Hemodynamic indices measured during sinus rhythm are shown in Figure 1A through 1C. As reported previously, 17, 20 left ventricular end-diastolic pressure and left ventricular systolic pressure changed gradually ( Figure 1A and 1B), whereas LA pressure increased at 1 week ( Figure 1C ). Masson trichrome stains ( Figure I in the online-only Data Supplement) revealed progressive LA fibrosis, which became statistically significant 1 week after VTP onset ( Figure 1D ), concomitant with the appearance of an AF-maintaining substrate ( Figure 1E ). Figure 2 shows results of miR29b LA expression studies. Total LA expression decreased by 87% within 24 hours and remained significantly decreased at 1-week and 2-week VTP ( Figure 2A ). Expression in cardiac fibroblasts largely paralleled that in whole atrial tissue, with a substantial decrease in miR29b at 24-hour VTP (−92% versus control; p<0.001) and with values remaining reduced subsequently ( Figure 2B ). Sham dogs had miR29 expression values that were not significantly different from those of controls ( Figure II in the online-only Data Supplement), with mean values in fact greater than those of control dogs, excluding a role of surgery per se in the miR29 decrease seen in VTP dogs. Although we focused primarily on miR29b, because its copy number is double that of the miR29a and miR29c isoforms, we also measured the latter (which have the same target gene profile as miR29b) in canine atrial fibroblasts and found them to be significantly decreased ( Figure III in the online-only Data Supplement), with a time course similar to that of miR29b ( Figure 2B ). We also measured the expression levels of miR590 and miR133a/b, which have been implicated previously in nicotine-induced atrial fibrotic remodeling. The majority of miR29b mRNA targets are ECM genes, including collagen 1A1 (Col1A1), collagen 3A1 (Col3A1), and fibrillin (FBN).
5 Figure 3 shows the expression profiles of Col1A1, Col3A1, and FBN in isolated LA fibroblasts over time. Col1A1 gene expression ( Figure 3A ) roughly paralleled the development of fibrosis, increasing 9-fold at 1 week, with a further increase (15-fold) at 2 weeks. Col3A1 expression showed a similar pattern ( Figure 3B ). FBN expression also increased significantly at 2 weeks ( Figure 3C ).
Effects of Forced Alterations in miR29b Expression In Vitro
To directly assess changes in canine atrial fibroblast target gene expression resulting from altered miR29b expression in vitro, we used viral gene transfer to deliver a sponge construct designed to physically sequester miR29b by complementary binding to cause its cellular degradation (miR29b knockdown) and a miR29b-overexpressing virus to increase miR29b levels (schematic shown in Figure 4B ). GFP was included in a bicistronic fashion to determine infection efficiency, which was nearly 100% ( Figure 4A ).
Sponge-bearing virus infection decreased fibroblast miR29b expression by 68% ( Figure 4C ). This miR29b decrease was accompanied by significant increases in Col1A1 (+28%), Col3A1 (+19%), and FBN (+20%) mRNA expression ( Figure 4C , left). COL1A1 protein was measured from the supernatant of gene-transferred fibroblasts and was found to increase by ≈90% in miR29b knockdown cells versus GFP controls ( Figure 4C , right). The miR29b-overexpressing virus increased miR29b expression by 3-fold compared with a scrambled control virus ( Figure 4D ). MiR29b overexpression significantly reduced Col1A1, Col3A1, and FBN mRNA expression by 65%, 62%, and 61%, respectively ( Figure 4D , 
MicroRNA Plasma Concentrations and Atrial Tissue Expression in Humans
Because plasma levels of miRs are known to change in various diseases, we investigated miR29b changes in patients. Plasma miR29b levels were reduced significantly, by ≈50%, in both AF and CHF patients versus controls. When AF patients were subdivided into those with versus without CHF, miR29b expression was similar in patients with AF only and CHF only but was lower with both conditions concomitantly ( Figure 5A ). MiR21 plasma levels were also decreased in patients with AF (−61%) and CHF (−64%) versus non-CHF, non-AF controls ( Figure 5B), but there was no significant difference for patients with AF and CHF versus controls. No significant differences among groups were seen for miR133a and miR15, which was used as a negative control on the basis of previous findings 10 ( Figure 5C and 5D). Multivariable adjusted regression revealed that the relation between miR29b and AF, CHF, or both remained significant after accounting for age, sex, coronary artery disease, hypertension, diabetes mellitus, hypercholesterolemia, angiotensin-converting enzyme inhibitor or angiotensin II receptor type 1 blocker treatment, use of aldosterone antagonists, and use of statins (Table II in No statistically significant differences were seen for miR133 or miR15 among control, AF, CHF, and AF/CHF groups when all potential contributors were considered in model 3.
We then examined miR concentrations in right atrial appendage tissues from patients with or without AF. MiR29b tissue expression was decreased by 40% in paroxysmal AF patients and by 54% in chronic AF patients versus sinus rhythm patients ( Figure 6A ). MiR133a expression was similar in all groups ( Figure 6B ).
Manipulation of miR29b In Vivo With a Mouse Model
To assess directly the effect of decreased miR29b expression in vivo on collagen expression, a miR29b sponge carried by a cardiotropic adenoassociated virus (AAV-9) was used. Mice were injected systemically with either a GFP control construct or a sponge construct to decrease miR29b expression. Good myocardial infection was obtained with both ( Figure V in the online-only Data Supplement). Atrial COL1A1 mRNA levels increased by ≈45% in the sponge group compared with GFP control virus-injected mice ( Figure 7A ). Tissue collagen protein expression was assessed with Masson trichrome staining ( Figure 7B and 7C). Collagen content was approximately doubled in miR29b sponge-exposed hearts ( Figure 7B ).
Discussion
In this study, we demonstrated a rapid decrease of miR29b atrial expression in a canine CHF model of atrial fibrosis associated with an AF-maintaining substrate, followed by increased expression of miR29b ECM target genes, in particular the collagen components (Col1A1 and Col3A1) that constitute >90% of cardiac fibrotic tissue. 2 Manipulation of miR29b expression in the target cells (fibroblasts) produced changes consistent with an important collagen regulatory role. We further demonstrated that plasma levels of miR29b are decreased in AF and CHF patients, with further decreases in patients with both, even after accounting for potential confounding factors. In addition, atrial tissue levels of miR29b were decreased in AF patients. Mimicking CHFinduced decreases in miR29b expression with cardiac homing adenoassociated viral knockdown gene transfer in the mouse confirmed collagen upregulation.
Comparison With Previous Studies of Profibrotic MicroRNAs
Recent studies have pointed to a role for miR21, miR133a, and miR29b in tissue fibrosis. MiR21, upregulated via Smad3 signaling, promotes renal fibrosis. 21 Smad3-deficient mice show increased miR29b levels and no fibrosis after obstructive nephropathy. 22 MiR21 is upregulated in idiopathic pulmonary fibrosis, and antisense miR21 diminishes fibrosis in mice. 23 The role of miR21 in cardiac fibrosis is controversial. Thum et al 4 showed that inhibiting miR21 suppresses fibrosis in a mouse model of pressure overload. However, Patrick et al 24 showed that miR21 knockout mice display unchanged responses (including fibrosis) to cardiac stress. In a recent study, we found that miR21 knockdown with anti-miRs in post-MI rats decreases atrial fibrosis and AF duration. MiR133 is muscle specific, with relatively weak expression in fibroblasts, 6 and plays a major role in cardiomyocyte hypertrophy. 25 Transforming growth factor-β contains multiple putative binding sites for miR133, and miR133 downregulation contributes to increased transforming growth factor-β levels. MiR133 also binds to and inhibits connective tissue growth factor, which has profibrotic properties. 6 Whereas atrial fibroblast miR133 levels decreased in VTP dogs, atrial miR133 expression was unchanged in AF patients. Downregulation of miR29 has been identified as potentially pathogenic in a mouse model of hepatic fibrosis, 26 and miR29b is downregulated in patients with liver disease. Similarly, miR29b is inversely correlated with pulmonary fibrous tissue content in a mouse model of lung fibrosis. 27 MiR29b is also dysregulated in mice with experimental MI. 5 In right atrial appendage samples from mitral stenosis patients with AF, members of the miR29 family are downregulated (miR29a, −1.54; miR29b, −1.42; miR29c, −1.27 versus control), as is miR133a (−1.58 versus control). 28 MiR29b was also shown to increase with age in the aorta of mice and humans and was increased in patients with aortic aneurysm compared with control. 29 On the basis of the biology of miR29b and the fact that it was consistently decreased in the atria and plasma of our AF patients, we decided to fully investigate the role of miR29b in animal models. Changes in atrial miR29b expression occurred early in the pathophysiological process induced by VTP in dogs, when systolic pressure had decreased but cardiac filling pressures had not yet changed, and preceded collagen gene upregulation. These findings, along with the demonstration that miR29b expression directly regulates collagen genes in canine atrial fibroblasts and that in vivo miR29b knockdown enhances cardiac collagen expression in the mouse, suggest a role for miR29b in CHF-related atrial fibrosis and the associated enhancement in AF sustainability. Consistent with our findings in canine CHF, miR29 was also downregulated in CHF patients.
MicroRNAs as Biomarkers
Recent studies have highlighted the potential value of microRNA biomarkers for heart disease. Circulating levels of miR126, miR17, miR92a, and miR155 are decreased in patients with coronary artery disease. 10 In addition, miR1 and miR499 show increased expression in post-MI patients. 12, 30 Patients with heart failure have increased blood levels of several microRNAs. 11 Of these, only miR423-5p was significantly and independently correlated with the diagnosis of CHF. 11 In their screening microarray, miR29b concentrations were reduced by ≈33% relative to control, with borderline unadjusted statistical significance (p=0.052). Plasma levels of miR29b, miR21, and miR133a were unchanged in patients with diastolic dysfunction. 31 MiR150 was also shown to be decreased in AF patients versus healthy controls and was independently associated with AF. 32 Interestingly, changes in circulating microRNAs precede MI occurrence, with altered expression of 3 microRNAs associated with MI: miR216, miR223, and miR197. 33 We chose to focus on miRs involved in fibrosis. MiR133a was unchanged in both tissue and plasma of AF patients. MiR21 concentrations were decreased in plasma of AF and CHF patients, but after correction for associated conditions and drug therapy, they were no longer significantly different in AF patients. MiR29 showed the clearest and most coherent changes in both plasma and atria of AF patients and was also found to play a potentially significant role in collagen regulation. Extensive clinical studies will be needed to establish the potential value of miR29b and other candidate miRs in predicting the natural history and guiding management of AF. Further studies are also needed to understand the determinants of circulating miR concentrations and the manner in which they can aid in disease management and prevention.
Potential Mechanisms of miR29b Downregulation
Transforming growth factor-β has been implicated in miR29b downregulation 5, 26 and is upregulated in canine atrium after 24-hour VTP. 34 This timing corresponds to the onset of miR29b downregulation in the present study. However, transforming growth factor-β expression returns toward normal during continued VTP, 34 whereas in the present study miR29b expression remained decreased for at least 2 weeks, implicating additional mechanisms. A recent study pointed to a role of nuclear factor-κB (NF-κB) in miR29b downregulation. 35 There are 4 NF-κB binding sites near the transcriptional start site for miR29b; NF-κB activation represses promoter activity. NF-κB expression is increased in fibrotic myocardium of CHF patients, 36 and NF-κB is activated in the atria of AF patients. 37 NF-κB involvement may also contribute to the atrial-selective fibrosis (versus ventricular) commonly seen with cardiac pathology.
34,38
Potential Significance
Structural remodeling is an important paradigm in AF. 39 To our knowledge, our study is the first to report a potential role for miR29b in AF-related atrial profibrotic remodeling. Van Rooij et al 5 provided the first evidence indicating involvement of miR29b in the ventricular profibrotic response after MI. They found miR29 to be selectively expressed in cardiac fibroblasts and to be downregulated in the MI border zone. They demonstrated regulation of ECM gene expression by miR29b, implicating miR29b in the formation of post-MI scar and border zone fibrosis. The ability of miR29b overexpression to suppress collagen expression in atrial fibroblasts (Figure 4 ) points to the potential value of miR29 manipulation in influencing the development of the AF substrate.
Our study also points to miR29 as a potential AF plasma biomarker. Although much remains to be learned about circulating microRNAs, it has been shown that they are carried by microparticles and exchange information between cells. 40 There is great interest in noninvasive markers of atrial structural remodeling that could provide prognostic information and be helpful in assessing preventive approaches. 41 MiR29b, because of its potential pathophysiological significance, merits consideration, along with other recently described biomarkers in AF such as brain natriuretic peptide.
42
Potential Limitations
We chose to focus on miR29b because of its important role in post-MI ventricular fibrosis 5 and the consistent decrease of miR29 expression in the atria and plasma of AF patients. It is unlikely that a single microRNA is the sole determinant of structural remodeling in complex conditions such as AF or CHF. Indeed, the expression of a substantial number of microRNAs is altered in CHF and may be pathophysiologically important. 43, 44 MiR21 appears to play an important role in post-MI atrial fibrotic remodeling in rats, 9 and other candidates include miR133 and miR590. 7 The results of the present study indicate for the first time that miR29b is a strong candidate to play a pathophysiological role in atrial structural remodeling and is also an interesting candidate AF biomarker.
MiR29b was significantly downregulated at 24 hours, whereas significant fibrosis was apparent at 1 week. These results indicate a delay from miR29b downregulation to collagen accumulation. Some of this lag likely reflects the delay from downregulation of miR29b expression to the consequent upregulation of collagen gene expression, as well as the time needed for detectable collagen protein accumulation. Fibrous tissue content was nonsignificantly increased by ≈65% at 24 hours, and a highly significant, 5-fold increase was apparent at 1 week. Therefore, collagen content increased some time between 1 day and 1 week, with a lag not incompatible with a causative role for miR29b. In addition, other microRNAs and signaling systems may have been involved.
We used a specific animal model of CHF-associated AF. Extrapolation to clinical forms should be cautious, although it is intriguing that changes in miR29b plasma and tissue concentration of AF and CHF patients mirror our observations in the experimental model. We chose a lentiviral expression vector for in vitro miR29b expression manipulation because of its long-lasting expression and improved nuclear targeting. 45 However, there are other potentially effective means of modifying microRNA expression, including delivery of highly stable, chemically modified microRNA analogues. 5 In addition, we were able to achieve effective regulation of cardiac collagen expression with peripheral vein injection of an adenoassociated viral vector bearing a microRNA knockdown construct, and therefore cardiac-specific modulation of miR29 may be achievable with systemic administration. We tried to quantify miR29b knockdown by the sponge virus; however, this proved to be impossible because our qPCR probes cross-reacted with a component of the virus. We were unable to design alternate probes because of the very short length of miR29b.
MiR29 exists as 3 isoforms (a through c). Consistent with the bicistronic coupling of miR29b with miR29a and miR29c, the 3 miRs form a single miR29 family with consistent expression and biology. Accordingly, we saw changes in cardiac fibroblast expression of miR29a and miR29c in VTP dogs ( Figure  III in the online-only Data Supplement) similar to those that occurred with miR29b. We focused on miR29b because its gene copy number is twice that of miR29a and miR29c analogues (which have identical targeting) and because it is the most strongly expressed isoform in fibroblasts.
Conclusions
In an animal model of AF associated with VTP-induced CHF, miR29b levels are rapidly and strongly downregulated. Atrial fibroblast expression of the ECM genes COL1A1, COL3A1, and FBN is regulated by miR29b, and in vivo miR29b knockdown increases cardiac collagen expression. Plasma and atrial tissue samples from AF patients show decreased miR29b expression. Therefore, miR29b appears to be important both in terms of generation of the AF substrate and as a candidate biomarker for atrial remodeling. Restoring miR29 expression may be a potentially interesting approach to suppressing AFpromoting structural remodeling.
CLINICAL PERSPECTIVE
Despite a variety of advances, the management of atrial fibrillation (AF) remains challenging. Congestive heart failure (CHF) is a major predisposing factor for AF, and atrial fibrosis is known to be a significant component of the CHF-induced AF substrate. MicroRNAs (miRs) are small RNA sequences (18-22 nucleotides) that regulate protein transcription and mRNA stability. In the present study, we studied the role of miR29 as a potential contributor to the AF-maintaining fibrotic substrate caused by CHF, as well as a possible AF/CHF biomarker. We found that atrial miR29 is rapidly downregulated in a canine model of tachycardia-induced CHF, followed by upregulation of its extracellular matrix targets collagen I/III and fibrillin. Lentiviral-mediated knockdown of the most prevalent isoform miR29b in atrial fibroblasts (to mimic CHF-induced downregulation) increased the expression of collagen I/III and fibrillin, whereas miR29b enhancement suppressed extracellular matrix protein expression. MiR29b plasma levels were significantly decreased in patients with CHF or AF and were further decreased in patients with both AF and CHF, whereas 3 other miRs (miR21, miR133, and miR15) showed weak or absent relations with AF and CHF. MiR29b expression was also reduced in the atria of chronic AF versus sinus rhythm patients. In vivo knockdown of miR29b in mice via intravenous administration of a cardiotropic adenoassociated viral vector significantly increased atrial COL1A1 mRNA expression and cardiac tissue collagen content. We conclude that miR29 may contribute to the fibrotic AF-maintaining substrate in CHF and is altered in the plasma of patients with AF and/or CHF. Thus, miR29 shows promise as an AF biomarker and is a potential therapeutic target for AF prevention. 
Fibrosis assessment
Fibrosis was evaluated with Masson's trichrome staining. LA-sections from the free-wall and from the LA-appendage were cut into 5-µm sections along longitudinal and transverse planes.
Fibrosis was quantified by a blinded observer as previously described 2 and expressed as % cross-sectional area, excluding blood vessels and perivascular tissue. Results were averaged for each dog for statistical analysis.
Fibroblast isolation
Atrial cells were isolated as described previously. 3 Cells were then centrifuged at 800 rpm for 2 minutes to pellet cardiomyocytes. The supernatant was filtered through 0.2-µm mesh to remove any remaining cardiomyocytes and then centrifuged at 2,000 rpm for 10 minutes to pellet fibroblasts. The remaining supernatant was removed, 500-µL Trizol added and samples snap-frozen in liquid-N 2 and stored at -80°C for RNA-extraction and qPCR. These samples are referred to as freshly isolated fibroblasts.
RNA extraction and qPCR from canine atrial tissue
LA tissue samples were kept in liquid nitrogen and 30-50 mg of tissue from each sample was removed and pulverized using a mortar and pestle. One mL of Trizol (Invitrogen) was immediately added to each sample and the samples were homogenized using a Polytron device.
0.2 mL of chloroform was added to each sample and the manufacturer's protocol was followed to isolate RNA. After drying the pellet, total RNA was dissolved into 30 µL of RNase free water Table 1 for detailed primer information.
Fluorescence signals were detected in duplicate by qPCR (Stratagene Corp, La Jolla, Calif).
miR29b from tissue was normalized to HPRT, and miR29b from freshly isolated fibroblasts was normalized to the geometric mean of 4 reference genes: U6, HPRT, beta-actin and 18S. mRNA was referenced to beta-2-microglobulin in freshly isolated fibroblasts. All genes measured in the in vitro experiments were normalized to the geometric mean of 4 reference genes: HPRT, beta-actin, U6 and 18S. Each gene was detected in duplicate and analyzed with the delta-CT method.
Data was quantified using MxPro qPCR software.
Plasmid constructs
Mir29b knock-down
The lentiviral vector plasmid which encodes the mir29b decoy tag linked to GFP mRNA was As a negative control for mir29b knock-down we used a virus consisting of the pGIPZ vector plasmid without modification (Open Biosystems).
Lentiviral-mediated mir29b overexpression
The pLemir pri-mir29b over-expressing lentiviral vector plasmid was obtained from Open
Biosystems. The sequence-verification of the clone revealed that the purchased plasmid carried the pri-mir29b sequence in the opposite orientation with respect to the direction of transcription driven by the CMV promoter of the plasmid. The sequence analysis also showed that the pri-mir29b sequence can be mobilized by NotI and XhoI restriction enzymes with minimal flanking sequences. We sub-cloned the NotI-XhoI fragment of pLemir carrying the pri-mir29b
sequence in pGIPZ at its unique NotI-XhoI sites, which resulted in a CMV-GFP-pri-mir29b
construct with the correct orientation of pri-mir29b.
As a negative control for the mir29b over-expressing virus, a virus over-expressing a scrambled shRNA in a pri-miRNA context (shRNAmir) was used. The scrambled shRNAmir over-expressing plasmid was generated as follows. The empty pGIPZ lentivirus vector plasmid carrying the mRNA-context sequence but no shRNA was obtained from Open Biosystems. The
EcoRI site of pGIPZ located at position 5394 was removed by partial EcoRI digestion and Klenow fill-in, resulting in pGIPZΔEcoRI. This modification allowed the direct cloning of the scrambled shRNAmir construct in pGIPZ between XhoI, 2654 and EcoRI, 2678 sites. In the design of the scrambled shRNAmir and during the rest of the cloning procedure we followed protocols in. 4 Briefly, a 97bp long synthetic oligonucleotide (5` TGCTGTTGACAGTGAGCGCCGATATCAGCAGATAATGAAATAGTGAAGCCACAGATGT A TTTCATTATCTGCTGATATCGTTGCCTACTGCCTCGGA 3`, passanger strand, loop, guide strand) was PCR amplified by 5`
CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG sense and 5`
CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA antisense primers, carrying XhoI and EcoRI restriction sites, respectively. PCR product was cloned in pGIPZΔEcoRI at XhoI, EcoRI sites. Sequence identity of the resulting clone was verified by sequencing.
Lentivirus packaging plasmids
The psPAX2 and pMD2.G lentivirus packaging plasmids were obtained from Didier Trono`s laboratory (http://tronolab.epfl.ch/, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland) through Addgene (Addgene plasmid 12260 and 12259).
All plasmids were amplified in E. coli DH5α and purified by Nucleobond anion exchange columns (Macherey-Nagel, Bethlehem, PA, USA) following the manufacturer's instructions.
Lentivirus production
The Hek293T/17 cell line we used for producing lentivirus production was obtained from ATCC Virus particles were concentrated by ultracentrifugation at 47000 g (RCF average) for 2 hours in a swinging bucket rotor, re-dissolved in sterile PBS containing 1% BSA and stored at -80°C in aliquots. Virus preparations were titrated on Hek293T/17 cells.
In vitro manipulation of fibroblast miR29b expression
LA fibroblasts were isolated as described previously 5 with the exception that DMEM (Gibco)
supplemented with 10% FBS and 1% penicillin-streptomycin was used instead of Medium 199.
At near-confluence (5-7 days) fibroblasts were trypsinized, counted, and plated in 12-well dishes at 100,000 cells/well. After 4-6 hours for recovery, cells were transfected with lenti-viral constructs at 50 m.o.i. Cells were kept in culture for 3-5 days post-infection and then samples were collected for qPCR by adding 500 µL/well Trizol followed by snap-freezing and storage at -80°C.
MiR29b knock-down was achieved with a lentivirus over-expressing a competitive inhibitor sequence of mir29b (mir29b-sponge) coupled to GFP mRNA. Lentivirus over-expressing GFP only served as a negative control. Forced miR29b-over-expression was obtained with a lentivirus over-expressing the pri-mir29b sequence. As a negative control in the over-expression experiments we used a virus with a scrambled shRNA embedded in a pri-miRNA context.
Adenoassociated-virus constructs
For in vivo mir29b-sponge delivery, we used a self-complementary adenoassociated virus-based vector system. The scAAV-GFP vector plasmid was a kind gift from K. Reed Clark (Addgene plasmid number 21893). 6 The sponge sequence was PCR amplified from a synthetic 
Adenoassociated-virus production
Hek293T/17 cells were grown in 10-cm diameter tissue-culture dishes in DMEM, supplemented with 10% serum. Subconfluent dishes were transfected with 4 µg of vector plasmid and 12 µg of pDG9 packaging-plasmid in the presence of 64 µg polyethyleneimine (25 kDa, linear, Polysciences Inc.). Cells were harvested 48-72 hours post-transfection and were lysed by repeated freeze-thaw cycles. Lysates were treated with Bensonase nuclease and were separated on iodixanol density-gradients as described by Zolotukhin et al. 7 The AAV fractions collected from the 25% iodixanol layer were desalted and formulated by using the Amicon Ultra centrifugal filter units (100 kDa, Millipore) into Ringer`s lactate solution. Virus vector preparations were aliquoted and stored at -80°C.
Genome copy numbers of AAV vector preparations were determined by real-time qPCR using the 5` ACGACGGCAACTACAAGA sense and 5` TGCTTGTCGGCCATGATA antisense primers specific for the eGFP ORF carried by both the mir29b-sponge and the GFP control virus.
Standard curves were constructed from serial dilutions of the scAAV-GFP plasmid and were run in parallel with the unknown AAV vector preparations. AAV vector genome copy numbers were determined by interpolating from the standard curve.
In vivo manipulation of mouse cardiac miR29b expression
Animal-handling procedures followed National Institutes of Health guidelines 
Quantification of collagen content by Western blot
Fibroblasts were infected with lentiviruses (miR29b-sponge or miR29b over-expressing) as described above. Twenty-four hours post-infection, a medium-change was performed and 1 mL of medium was added per well of a 12-well dish. Fibroblasts were then allowed to grow for 5 days without changing medium. After this 5-day period, the medium was removed and immediately frozen in liquid-N 2 . Fibroblasts were trypsinized and counted. Since collagen is a secreted protein and most collagen that is produced moves into the extracellular space, collagen was assayed in the medium and results normalized to cell number per well.
For collagen-detection, a 6% SDS-PAGE gel was loaded with supernatant mixed with loading buffer at a maximum volume of 60 µL and a minimum of 54 µL. Proteins were separated by electrophoresis followed by transfer to nitrocellulose membranes. Membranes were blocked overnight with 3% bovine serum albumin and incubated for 1 hour at room temperature with primary antibody to collagen-I (1/20,000 MD Sciences, MD20151). After membranes were washed, they were incubated with anti-rabbit secondary antibody (1/10,000, Jackson) conjugated to horseradish peroxidase for 1 hour at room temperature. Signals were detected with chemiluminescence and quantified with Biorad Quantity One software.
Determination of miRNAs in plasma of AF patients
Patients
To further investigate a potential role of miRNAs as a biomarker in AF patients we investigated miRNA plasma levels in AF patients (n=33). Thirty-three patients followed for persistent AF constituted the AF-population (patients with permanent or paroxysmal AF were excluded). AF classification was performed according to the AHA/ACC guidelines for the management of patients with atrial fibrillation 8 and AF was considered persistent when the arrhythmia sustained beyond 7 days and termination with pharmacological therapy or direct-current (DC) cardioversion did not fail >2 consecutive times. In addition, a EHRA AF symptom score was assessed at admission according to ESC guidelines for management of atrial fibrillation (EHRA score: EHRA I "no symptoms"; EHRA II "mild symptoms", normal daily activity not affected;
EHRA III "severe symptoms", normal daily activity affected; EHRA IV "disabling symptoms", normal daily activity discontinued). 9 Patients were included when the initial ECG recording at admission showed AF (an irregular atrial rhythm with no discernable P waves in the ECG), which persisted ≥7d; patients had to be in a compensated clinical cardiac and pulmonary state and show heart rate of 50-100 bpm (during AF) at the time of blood sampling. Blood samples were taken while the patients were still in AF. In addition, thirty-two patients with CHF and no history Controls were patients from the surgical outpatient clinic (n=30), in whom heart disease had been excluded by ECG and clinical examination. In addition, we excluded control patients with chronic inflammatory diseases, history of cancer, liver disease or neurodegenerative disease.
Following Mitchell et al. 11 we measured miRNA in plasma.
Blood processing
Blood samples from patients were obtained with informed consent under institutional review board-approved protocols. Blood of all subjects was collected via a direct venous puncture into 9 ml EDTA containing tubes (Sarstedt Monovette). All blood was processed for isolation of plasma within 4 hours of collection. Blood was processed by spinning at 4000 rpm for 20 minutes at room temperature. Plasma was carefully transferred to a fresh RNAse/DNAse free tube and stored at -80ºC.
RNA Isolation
Total RNA was isolated using the miRNeasy kit (Qiagen) and a modified protocol based on Dimmeler et al. 12 Plasma was thawed on ice and 400 µL EDTA-plasma was mixed with 4000 µL TRIzol (Invitrogen), incubated for 5 minutes at room temperature and subsequently mixed with 800 µL chloroform. The organic and aqueous phase was separated by centrifugation. The aqueous phase containing the RNA was carefully removed and RNA was precipitated by addition of 100% ethanol. The mixture was applied to a RNeasy Mini spin column, washed several times and RNA was eluted by addition of 35 µL RNase-free water (95°C).
To date, no housekeeping miRNA has been established and validated to normalize for the miRNA content. Therefore, we chose to use a fixed volume of plasma per sample and a synthetic
Caenorhabditis elegans miR-39 (cel-miR-39, 20 fmol/sample, synthesized by Qiagen) as a spiked-in control to normalize for individual RNA-isolation-related variations. Twenty fmol cel-miR-39 were introduced to each plasma sample after addition of denaturating Qiazol solution.
For each RNA sample, the C. elegans spiked-in miRNAs were measured using TaqMan qRT-PCR assays (Applied Biosystems).
Measurement of miRNA Levels in Plasma with TaqMan qPCR Assays
A fixed volume of diluted RNA (5 µL) was subjected to reverse transcription using the TaqMan Supplemental Figure 4 . The expression of miR-590 (A), miR-133a (B) and miR-133b (C) was measured in freshly isolated atrial fibroblasts from CTL and VTP
